2017
DOI: 10.1371/journal.pone.0182887
|View full text |Cite
|
Sign up to set email alerts
|

Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets

Abstract: ObjectiveInvestigate a combination of two clinically tested drugs, the NR2B antagonist Radiprodil and the A2A antagonist Tozadenant in the MPTP-treated marmoset model of Parkinson’s Disease (PD).BackgroundIn PD, there remains a need for the development of non-dopaminergic drugs to effectively treat the motor symptoms without the induction of L-Dopa-induced motor complications.MethodsClinically relevant doses of Radiprodil and Tozadenant were given both alone and in combination without the addition of L-Dopa, a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0
3

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 36 publications
(44 reference statements)
0
5
0
3
Order By: Relevance
“…The combination therapy of NR2B-selective antagonists with other drugs was also applied. For example, the combination of the GluN2B-selective antagonist Radiprodil and the A 2A antagonist Tozadenant led to significant motor improvement both in 6-OHDA-lesioned rats and MPTP-lesioned marmosets [74,75]. In addition, a series of photo-switchable antagonists for the modulation of NMDA receptors have been synthesized by researchers.…”
Section: Key Targets Of Glutamate Receptors In Pd Treatmentmentioning
confidence: 99%
“…The combination therapy of NR2B-selective antagonists with other drugs was also applied. For example, the combination of the GluN2B-selective antagonist Radiprodil and the A 2A antagonist Tozadenant led to significant motor improvement both in 6-OHDA-lesioned rats and MPTP-lesioned marmosets [74,75]. In addition, a series of photo-switchable antagonists for the modulation of NMDA receptors have been synthesized by researchers.…”
Section: Key Targets Of Glutamate Receptors In Pd Treatmentmentioning
confidence: 99%
“…The strong rationale for using mGlu4 as a therapeutic target in PD is further supported by preclinical evidence that shows that positive allosteric modulators (PAM) of mGlu4 reduce motor disability in rodent models of PD . Successful transition to clinical trials in PD requires a safe, brain‐penetrant, target‐specific drug with proven therapeutic efficacy in the MPTP‐lesioned macaque model …”
mentioning
confidence: 99%
“…Klinische Studien bestätigen, dass A 2A Rezeptorantagonisten, wie Istradefyllin, Tozadenant oder Preladenant, zusammen mit der Einnahme von L-Dopa oder D 2 -Rezeptoragonisten, die therapeutischen Effekte dieser amplifizieren können [27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45].…”
Section: Studien Zur Motorikunclassified